LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Repare Begins Clinical Trial Combining RP-3467 and PARP Inhibitor Olaparib to Fight Advanced Cancers
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Express News | Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of Rp-3467, a PolΘ Atpase Inhibitor
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Hold Rating on Repare Therapeutics Amidst Early Promising Clinical Results and Safety Concerns
Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics
12 Health Care Stocks Moving In Monday's After-Market Session
Repare Therapeutics Reports 'Encouraging' Phase 1 Camonsertib Combo Data
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination With Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Express News | Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination With Radiotherapy Treatment Presented at the Astro Annual Meeting
Repare Therapeutics Inc. (NASDAQ:RPTX) Is Definitely on the Radar of Institutional Investors Who Own 36% of the Company
Express News | Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients With Metastatic Gynecologic Cancers
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Data and Market Potential
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Repare Therapeutics Inc. (NASDAQ:RPTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Repare Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1/2 Cancer Trial Data at the European Society of Medical Oncology Congress (ESMO).